Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 4 1Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Cyclophosphamide 119Specimen Handling 104pembrolizumab 102Magnetic Resonance Spectroscopy 96fludarabine 92Biopsy 79Injections 53Nivolumab 41venetoclax 40Bevacizumab 40Fluorouracil 38Paclitaxel 37Cisplatin 36Cetuximab 35Carboplatin 35Gemcitabine 31fludarabine phosphate 30Radiotherapy 30Oxaliplatin 30Leucovorin 28Immunotherapy, Adoptive 25Drug Therapy 25Ipilimumab 24Azacitidine 23Irinotecan 21130-nm albumin-bound paclitaxel 21tislelizumab 20Temozolomide 20Radiation 20atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Quality of Life × Clear all
NCT07340853 2026-03-10

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

University of California, San Francisco

Phase 1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡